1. Home
  2. APWC vs EQ Comparison

APWC vs EQ Comparison

Compare APWC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APWC

Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)

HOLD

Current Price

$1.34

Market Cap

60.6M

Sector

Industrials

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.97

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APWC
EQ
Founded
1996
2017
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
64.5M
IPO Year
1997
2018

Fundamental Metrics

Financial Performance
Metric
APWC
EQ
Price
$1.34
$1.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
3.4K
599.0K
Earning Date
03-31-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.29
52 Week High
$2.34
$2.70

Technical Indicators

Market Signals
Indicator
APWC
EQ
Relative Strength Index (RSI) 28.72 51.23
Support Level N/A $1.22
Resistance Level $1.47 $2.30
Average True Range (ATR) 0.05 0.22
MACD -0.00 -0.03
Stochastic Oscillator 9.52 33.64

Price Performance

Historical Comparison
APWC
EQ

About APWC Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)

Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: